Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kimberly Morin

Physician Assistant Arnold, MD Physician Assistant

NPI 1558790105 CMS profile 10722188

1509 Ritchie Hwy, Arnold, MD 21012

Open in the dashboard

General payments

$2,097

110 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kimberly Morin of Arnold, MD is reported in the CMS Open Payments database as having received $2,097 across 110 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $530 24
2024 General $398 21
2023 General $322 17
2022 General $285 16
2021 General $562 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kimberly Morin
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Kimberly Morin were reported at $530. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Kimberly Morin Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $562 $132 $37–$438 $132
2022 $285 $155 $48–$522 $149
2023 $322 $167 $52–$557 $160
2024 $398 $178 $55–$600 $164
2025 $530 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $503 27 payments
  2. Novo Nordisk Inc $430 20 payments
  3. Pfizer Inc. $140 9 payments
  4. GlaxoSmithKline, LLC. $137 7 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $116 7 payments
  6. Abbott Laboratories $95 5 payments
  7. Astellas Pharma US Inc $91 5 payments
  8. Lilly USA, LLC $87 5 payments
  9. Boston Scientific Corporation $70 2 payments
  10. Jazz Pharmaceuticals Inc. $58 3 payments
  11. Other $371 20 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,097 110 payments
Products named General payments · program years 2021–2025
  1. Ozempic $287 13 payments
  2. RYBELSUS $287 13 payments
  3. LINZESS $192 8 payments
  4. CREON $167 7 payments
  5. UBRELVY $138 8 payments
  6. ELIQUIS $121 8 payments
  7. SHINGRIX $120 6 payments
  8. XIFAXAN $116 7 payments
  9. Wegovy $112 5 payments
  10. Veozah $91 5 payments
  11. Other $1,448 83 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 54 drugs

Part D claims

1,771

Median for Physician Assistant: 241

Drug cost

$40,074

Median for Physician Assistant: $4,110

Branded share of claims

12.5%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 15 $14,497
Lisdexamfetamine Dimesylate Generic 12 $2,614
Rosuvastatin Calcium Generic 115 $1,966
Levothyroxine Sodium Generic 147 $1,745
Atorvastatin Calcium Generic 118 $1,572
Metoprolol Succinate Generic 61 $1,467
Synthroid Levothyroxine Sodium Brand 22 $1,245
Bupropion Xl Bupropion Hcl Brand 31 $1,207
Albuterol Sulfate Hfa Albuterol Sulfate Brand 35 $1,142
Valacyclovir Valacyclovir Hcl Brand 20 $859

The 10 drugs with the highest cost, of 54 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 88 billing codes

Paid by Medicare

$80,420

Of which drugs: $3,641

Medicare patients

356

Average age 73

Services billed

3,030

246 women, 110 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 44%
Depression 26%
Diabetes 19%
Ischemic heart disease 19%
Osteoporosis 17%
Chronic kidney disease 15%
Cancer 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 42 42 $3,436

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Veozah
  • Astellas Pharma US Inc $56
$56 — —
RYBELSUS
  • Novo Nordisk Inc $52
$52 — —
Ozempic
  • Novo Nordisk Inc $52
$52 15 —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $52
$52 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $25
$25 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

110 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record